Latest filingSep 08, 2026Most recent Form 4
MDCX
Medicus Pharma Ltd.
Insider activity for last month from 08/09 to 09/09. Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total buying$00 buys
Total selling$00 sells
Net open-market+$05 insiders
Open-market mix
Buy vs sell distribution by transaction countInsider activity report
Monthly open-market purchase and sale counts Buys Sells
Transaction codes
By Form 4 transaction code in selected period10transactions
- A · Grants / awards · dominant10 · 100%
Activity by reported role
A joint filing can contribute to multiple roles10transactions
- Chief executive officer · dominant2 · 20%
- CMO2 · 20%
- COO2 · 20%
- CSO2 · 20%
- PRES2 · 20%
Distinct insiders active
Reporting-owner CIKs by month · peak Sep 2026 (5)Aug 2026Sep 2026
Reported Holdings After
Separated by insider, security, and ownership typeBokhari RazaCommon Shares, no par value · Direct
2,941,176Sep 04, 2026
Bokhari RazaStock Option (right to buy) · Direct
500,000Sep 04, 2026
Bonner Carolyn F.Common Shares, no par value · Direct
1,489,493Sep 04, 2026
Bonner Carolyn F.Stock Option (right to buy) · Direct
250,000Sep 04, 2026
Brennan Edward J.Stock Option (right to buy) · Direct
100,000Sep 04, 2026
Brennan Edward J.Common Shares, no par value · Direct
674,735Sep 04, 2026
Mehmud FaisalStock Option (right to buy) · Direct
250,000Sep 04, 2026
Mehmud FaisalCommon Shares, no par value · Direct
1,470,588Sep 04, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Each cell is one day · intensity = transactions · buys green, sells redAug 09 → Sep 09
LessMore
Top insiders
By absolute net value across the selected period- BR+$501.5k
- MF+$250.7k
- BF+$250.7k
- SA+$125.4k
- BJ+$100.3k
Filing detail checks
Secondary metrics for the selected periodFiling-only signals
Deterministic matches in the selected period
No filing-only signal badges matched this period.
MDCX transaction history
Filters apply within this company and selected period by default| Ticker | Insider | Role | Type | Shares | Value | Code | Signals | 90d return | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|---|
| MDCX | Smith Andrew Alasdair | COO | grant | 125k | $0 | A | — | — | 09/08 | 09/04 |
| MDCX | Smith Andrew Alasdair | COO | grant | 735k | $12.5M | A | — | — | 09/08 | 09/04 |
| MDCX | Mehmud Faisal | CMO | grant | 250k | $0 | A | — | — | 09/08 | 09/04 |
| MDCX | Mehmud Faisal | CMO | grant | 1.47M | $25.0M | A | — | — | 09/08 | 09/04 |
| MDCX | Brennan Edward J. | CSO | grant | 100k | $0 | A | — | — | 09/08 | 09/04 |
| MDCX | Brennan Edward J. | CSO | grant | 588k | $10.0M | A | — | — | 09/08 | 09/04 |
| MDCX | Bonner Carolyn F. | PRES | grant | 250k | $0 | A | — | — | 09/08 | 09/04 |
| MDCX | Bonner Carolyn F. | PRES | grant | 1.47M | $25.0M | A | — | — | 09/08 | 09/04 |
| MDCX | Bokhari Raza | CEO | grant | 500k | $0 | A | — | — | 09/08 | 09/04 |
| MDCX | Bokhari Raza | CEO | grant | 2.94M | $50.1M | A | — | — | 09/08 | 09/04 |
Medicus Pharma Ltd. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at Medicus Pharma Ltd.?
Smith Andrew Alasdair, Mehmud Faisal, Brennan Edward J., Bonner Carolyn F., Bokhari Raza.
When was the latest reported open-market purchase?
No code-P purchase is available for this period.
When was the latest reported open-market sale?
No code-S sale is available for this period.
What is the recent purchase and sale balance?
No code-P purchases or code-S sales were reported in the selected period.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.